Entera Bio ENTX 深 沪
等待开盘 07-08 09:30:00 美东时间
1.66
-0.050
-2.92%
华盛通- 最 高1.72
- 今 开1.72
- 成交量 22.60万股
- 最 低 1.61
- 昨 收 1.71
- 总市值 8182.18万
- 52周最高 3.22
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 0.91
- 委 比 68.97%
- 总股本 4929.02万
- 历史最高 10.16
- 量 比 0.59
- 振 幅 6.43%
- 历史最低 0.472
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Reported Earlier: Entera Bio Receives FDA's Positive Feedback For Its Phase 3 Registrational Protocol For EB613 Tablet In Development To Treat Osteoporosis
Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on its Phase 3 registrational protocol for EB613 (oral PTH(1-34), teriparatide), the first...
06-23 00:32
Entera Bio Presents Oral Presentation Titled Transforming Anabolic Treatments For Osteoporosis: Reports Phase 1 Data Showing Single-Tablet EB613 Matches Forteo PK/PD Profile
Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported comparative Phase 1 data evaluating single-tablet and multi-tablet oral EB613 with Forteo® (teriparatide SC injection, Eli Lilly). The oral presentation "Transforming Anabolic Trea...
06-15 20:50
Entera Bio Announces Presentations Of New Data Supporting Its Oral Peptide Pipeline At The Annual Endochrine Society Meeting On June 13-16
Abstract Title: Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 StudySession Title: Late-Breaking Oral
05-28 20:54
Entera Bio Faces Elevated Operational Risks Amid Escalating Middle East Geopolitical Tensions
Entera Bio (ENTX) has disclosed a new risk, in the Economy & Political Envi...
05-10 14:01
Entera Bio Highlights Q1 2026 Progress and Financing
Entera Bio ( ($ENTX) ) has issued an update. Entera Bio reported first-quarter ...
05-09 04:53
Entera Bio Q1 EPS $(0.07) Beats $(0.08) Estimate
Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.06) per share from the
05-09 04:06
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio Ltd. reported Q1 2026 financial results and business updates, highlighting progress in its oral peptide therapeutics pipeline. Key developments include the submission of a streamlined Phase 3 protocol for EB613, an oral anabolic tablet for postmenopausal osteoporosis, and expanded collaboration with OPKO for EB612, an oral long-acting PTH tablet for hypoparathyroidism. Additionally, data for EB618, an oral dual GLP-1/glucagon tablet fo...
05-08 20:05
OPKO Health Q1 2026 Earnings Call: Complete Transcript
OPKO Health (NASDAQ:OPK) reported first-quarter financial results on Tuesday. T...
04-29 16:34
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
HC Wainwright & Co. Maintains Buy on Entera Bio, Lowers Price Target to $9
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entera Bio (NASDAQ:ENTX) with a Buy and lowers the price target from $10 to $9.
04-27 19:43
